These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 15467309

  • 21. Response of factor VIII/von Willebrand factor to intranasal DDAVP in healthy subjects and mild haemophiliacs (with observations in patients with combined deficiency of factors V and VIII).
    Garcia VV, Silva IA, Borrasca AL.
    Thromb Haemost; 1982 Aug 24; 48(1):91-3. PubMed ID: 6813999
    [Abstract] [Full Text] [Related]

  • 22. Desmopressin (DDAVP) in bleeding disorders of childhood.
    Sutor AH.
    Semin Thromb Hemost; 1998 Aug 24; 24(6):555-66. PubMed ID: 10066151
    [Abstract] [Full Text] [Related]

  • 23. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov 24; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 24. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR, Tuller J, Johnson JA.
    Haemophilia; 1999 Mar 24; 5(2):88-95. PubMed ID: 10215955
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effects of desmopressin on hemostasis in patients with liver cirrhosis.
    Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG.
    Haemostasis; 1995 Mar 24; 25(5):241-7. PubMed ID: 7489963
    [Abstract] [Full Text] [Related]

  • 27. [Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets].
    Martínez-Murillo C, Quintana-González S, Ambriz-Fernández R, Arzate-Hernández G, Gutiérrez-Romero M, Gaminio-Gómez E.
    Rev Invest Clin; 1997 Mar 24; 49(4):281-6. PubMed ID: 9707993
    [Abstract] [Full Text] [Related]

  • 28. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM, Avello AG, Vecino A, Cerveró C, Laraña JG, Fuertes IF, Villarrubia J, López J, de Oteyza JP, Velasco JL, Cantalapiedra A, Herrera P, Herrero S, Navarro JL.
    Med Clin (Barc); 1998 Nov 14; 111(16):601-3. PubMed ID: 9881332
    [Abstract] [Full Text] [Related]

  • 29. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
    Pfueller SL, Howard MA, White JG, Menon C, Berry EW.
    Thromb Haemost; 1987 Dec 18; 58(4):1060-3. PubMed ID: 3502198
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
    Casonato A, Steffan A, Pontara E, Zucchetto A, Rossi C, De Marco L, Girolami A.
    Thromb Haemost; 1999 Feb 18; 81(2):224-8. PubMed ID: 10063996
    [Abstract] [Full Text] [Related]

  • 33. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M, Karapinar DY, Balkan C, Ay Y, Kavakli K.
    Clin Appl Thromb Hemost; 2011 Oct 18; 17(5):441-8. PubMed ID: 20460340
    [Abstract] [Full Text] [Related]

  • 34. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
    Brommer EJ, Van den Wall Bake AW, Dooijewaard G, van Loon BJ, Emeis JJ, Weening JJ.
    Thromb Haemost; 1994 Jan 18; 71(1):19-25. PubMed ID: 8165642
    [Abstract] [Full Text] [Related]

  • 35. [The relationship between hemostatic changes in liver cirrhosis patients with different degrees of liver lesions in reference to Child-Pugh scores].
    Cong YL, Wei YX, Zhang LW, Yin ZJ, Bai J.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan 18; 13(1):31-4. PubMed ID: 15670488
    [Abstract] [Full Text] [Related]

  • 36. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).
    Köhler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E.
    Thromb Haemost; 1986 Feb 28; 55(1):108-11. PubMed ID: 3085261
    [Abstract] [Full Text] [Related]

  • 37. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
    Sultan Y, Loyer F, Venot A.
    Nouv Rev Fr Hematol (1978); 1992 Feb 28; 34(1):55-60. PubMed ID: 1523100
    [Abstract] [Full Text] [Related]

  • 38. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
    Kaufmann JE, Vischer UM.
    J Thromb Haemost; 2003 Apr 28; 1(4):682-9. PubMed ID: 12871401
    [Abstract] [Full Text] [Related]

  • 39. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD, Kunz D, Wirtz DC.
    Am J Hematol; 2002 May 28; 70(1):64-71. PubMed ID: 11994985
    [Abstract] [Full Text] [Related]

  • 40. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.
    Erem C, Hacihasanoğlu A, Celik S, Ovali E, Ersöz HO, Ukinç K, Deger O, Telatar M.
    Med Princ Pract; 2005 May 28; 14(1):22-30. PubMed ID: 15608477
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.